ofloxacin has been researched along with Skin Diseases, Infectious in 16 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Skin Diseases, Infectious: Skin diseases caused by bacteria, fungi, parasites, or viruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The in vitro activity of levofloxacin was compared to the activities of ofloxacin, ciprofloxacin, ampicillin-sulbactam (2:1), cefoxitin, and metronidazole for a selected group of anaerobes (n = 175) isolated from skin and soft tissue infections by using the National Committee for Clinical Laboratory Standards-approved Wadsworth method." | 7.70 | In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. ( Finegold, SM; Molitoris, D; Molitoris, E; Wexler, HM, 1998) |
| "The efficacy and safety of ofloxacin for the treatment of pneumonia, urinary infection and skin infections in the institutionalized elderly is being studied in a multicenter North American trial." | 5.07 | Ofloxacin use in a geriatric population. ( Alessi, P; Cullison, J; Degelau, J; Meyers, B; Nicolle, LE, 1991) |
| "The in vitro activity of levofloxacin was compared to the activities of ofloxacin, ciprofloxacin, ampicillin-sulbactam (2:1), cefoxitin, and metronidazole for a selected group of anaerobes (n = 175) isolated from skin and soft tissue infections by using the National Committee for Clinical Laboratory Standards-approved Wadsworth method." | 3.70 | In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. ( Finegold, SM; Molitoris, D; Molitoris, E; Wexler, HM, 1998) |
| "Ofloxacin therapy was administered an average of 45 days per patient, and was well tolerated." | 2.67 | Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents. ( Eron, LJ; Gentry, LO, 1992) |
| "Oral levofloxacin was also similar in efficacy to amoxicillin/clavulanic acid or oral clarithromycin in patients with acute maxillary sinusitis treated for 7 to 14 days." | 2.40 | Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. ( Lamb, HM; Langtry, HD, 1998) |
| "Ofloxacin was determined to have the widest spectrum of activity and potential empiric use (90." | 1.28 | Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group. ( Erwin, ME; Jones, RN; Reller, LB; Rosati, LA; Sanchez, ML, 1992) |
| "Ofloxacin was well tolerated and efficacious in the treatment of skin and soft tissue infections including those caused by staphylococci and streptococci." | 1.28 | Therapy of serious skin and soft tissue infections with ofloxacin administered by intravenous and oral route. ( Augustinsky, JB; Lentino, JR; Pachucki, CT; Weber, TM, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (18.75) | 18.7374 |
| 1990's | 13 (81.25) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujita, K | 1 |
| Nakano, M | 1 |
| Nonami, E | 1 |
| Shishiba, T | 1 |
| Katsumata, M | 1 |
| Horie, N | 1 |
| Watanabe, R | 1 |
| Kukita, A | 1 |
| Watanabe, S | 1 |
| Someya, T | 1 |
| Nichols, RL | 1 |
| Smith, JW | 1 |
| Gentry, LO | 4 |
| Gezon, J | 1 |
| Campbell, T | 1 |
| Sokol, P | 1 |
| Williams, RR | 1 |
| Wexler, HM | 1 |
| Molitoris, E | 1 |
| Molitoris, D | 1 |
| Finegold, SM | 1 |
| Langtry, HD | 1 |
| Lamb, HM | 1 |
| Lipsky, BA | 1 |
| Yarbrough, DR | 1 |
| Walker, FB | 1 |
| Powers, RD | 2 |
| Morman, MR | 1 |
| Kanzaki, H | 2 |
| Torigoe, R | 1 |
| Yamada, T | 1 |
| Abe, Y | 1 |
| Shimoe, K | 1 |
| Akiyama, H | 1 |
| Arata, J | 2 |
| Umemura, S | 1 |
| Katayama, H | 1 |
| Nishihara, O | 1 |
| Jones, RN | 1 |
| Reller, LB | 1 |
| Rosati, LA | 1 |
| Erwin, ME | 1 |
| Sanchez, ML | 1 |
| Eron, LJ | 1 |
| Lentino, JR | 1 |
| Augustinsky, JB | 1 |
| Weber, TM | 1 |
| Pachucki, CT | 1 |
| Nicolle, LE | 1 |
| Degelau, J | 1 |
| Alessi, P | 1 |
| Cullison, J | 1 |
| Meyers, B | 1 |
| Fujimoto, W | 1 |
| Fujiwara, H | 1 |
| Wallace, RJ | 1 |
| Bedsole, G | 1 |
| Sumter, G | 1 |
| Sanders, CV | 1 |
| Steele, LC | 1 |
| Brown, BA | 1 |
| Smith, J | 1 |
| Graham, DR | 1 |
| Rodriguez-Gomez, G | 1 |
| Zeluff, BJ | 1 |
| Khoshdel, A | 1 |
| Price, M | 1 |
| Nakamura, S | 1 |
| Minami, A | 1 |
| Nakata, K | 1 |
| Kurobe, N | 1 |
| Kouno, K | 1 |
| Sakaguchi, Y | 1 |
| Kashimoto, S | 1 |
| Yoshida, H | 1 |
| Kojima, T | 1 |
| Ohue, T | 1 |
3 reviews available for ofloxacin and Skin Diseases, Infectious
| Article | Year |
|---|---|
Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Topics: Animals; Anti-Infective Agents; Humans; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Skin | 1998 |
Therapy with newer oral beta-lactam and quinolone agents for infections of the skin and skin structures: a review.
Topics: Administration, Oral; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Age | 1992 |
[Cutaneous infection by Mycobacterium fortuitum biovariant "third group"--a case report and bacteriological examination of the isolate].
Topics: Adult; Anti-Bacterial Agents; Drug Resistance, Microbial; Female; Humans; Mycobacterium Infections, | 1990 |
7 trials available for ofloxacin and Skin Diseases, Infectious
| Article | Year |
|---|---|
[Comparative clinical study of DL-8280 and cefaclor for suppurative skin and soft tissue infections by a double-blind method].
Topics: Adult; Aged; Anti-Infective Agents; Bacterial Infections; Cefaclor; Cephalexin; Clinical Trials as T | 1984 |
Multicenter, randomized study comparing levofloxacin and ciprofloxacin for uncomplicated skin and skin structure infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ciprofloxac | 1997 |
Ofloxacin versus cephalexin for treating skin and soft tissue infections.
Topics: Cephalexin; Connective Tissue Diseases; Female; Humans; Male; Ofloxacin; Skin Diseases, Infectious; | 1992 |
Oral ofloxacin for infections caused by bacteria resistant to oral antimicrobial agents.
Topics: Administration, Oral; Adult; Aged; Bacterial Infections; Diabetes Complications; Drug Resistance, Mi | 1992 |
Soft tissue infections in the emergency department: the case for the use of 'simple' antibiotics.
Topics: Adult; Ambulatory Care; Bacterial Infections; Cephalexin; Connective Tissue Diseases; Drug Administr | 1991 |
Ofloxacin use in a geriatric population.
Topics: Aged; Cross Infection; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Ofloxacin; Pneumonia; | 1991 |
A comparative evaluation of oral ofloxacin versus intravenous cefotaxime therapy for serious skin and skin structure infections.
Topics: Administration, Oral; Adult; Bacteria; Cefotaxime; Female; Humans; Injections, Intravenous; Male; Mi | 1989 |
6 other studies available for ofloxacin and Skin Diseases, Infectious
| Article | Year |
|---|---|
In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Colony Count, Microbial; Humans; Levofloxacin; Microbial | 1998 |
[Levofloxacin in the field of dermatology].
Topics: Adolescent; Adult; Animals; Drug Evaluation; Drug Resistance, Microbial; Female; Humans; Levofloxaci | 1992 |
Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a Multicenter, National Comparative Activity Surveillance Study. The Ofloxacin Surveillance Group.
Topics: Anti-Infective Agents; Bacteria; Drug Resistance, Microbial; Enterobacteriaceae; Haemophilus influen | 1992 |
Therapy of serious skin and soft tissue infections with ofloxacin administered by intravenous and oral route.
Topics: Administration, Oral; Adult; Aged; Cellulitis; Humans; Infusions, Intravenous; Male; Microbial Sensi | 1991 |
Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy.
Topics: Adult; Aged; Ciprofloxacin; Drug Resistance, Microbial; Female; Humans; Male; Microbial Sensitivity | 1990 |
In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone.
Topics: Animals; Anti-Infective Agents; Bacteria; Bacterial Infections; Ciprofloxacin; Enoxacin; Fluoroquino | 1989 |